Biotech News

Adlai Nortye to Participate in Upcoming Investor Conferences

Adlai Nortye Ltd. (ANL)Adlai Nortye Ltd.2026-06-25 13:46 ESTConference / presentation

SINGAPORE and NORTH BRUNSWICK, N.J., March 3, 2026 – Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that members of its management team are scheduled to participate

Open original release

Related news

ANLAdlai Nortye Ltd.2026-06-25 13:46 EST

Adlai Nortye Reports Full Year 2024 Financial Results and Business Updates

ANLAdlai Nortye Ltd.2026-06-25 13:46 EST

Adlai Nortye Announces Topline Results of Phase III BURAN Trial Evaluating Buparlisib (AN2025) in Combination with Paclitaxel for Recurrent or Metastatic HNSCC

ANLAdlai Nortye Ltd.2026-06-25 13:46 EST

Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

ANLAdlai Nortye Ltd.2026-06-25 13:46 EST

Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

ANLAdlai Nortye Ltd.2026-06-25 13:46 EST

Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China

ANLAdlai Nortye Ltd.2026-06-25 13:46 EST

Adlai Nortye Announces $140.0 Million Private Placement Equity Financing

ANLAdlai Nortye Ltd.2026-06-25 13:46 EST

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations

ANLAdlai Nortye Ltd.2026-06-25 13:46 EST

Adlai Nortye Announces $150.0 Million Private Placement Equity Financing

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

JAGXJaguar Health2026-06-25 13:46 EST

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend

View all latest news

Adlai Nortye Ltd.

阿诺医药 is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ANLAdlai Nortye Ltd.2026-06-26 06:19 EST

Adlai Nortye Reports Full Year 2024 Financial Results and Business Updates

ANLAdlai Nortye Ltd.2026-06-26 06:19 EST

Adlai Nortye Announces Topline Results of Phase III BURAN Trial Evaluating Buparlisib (AN2025) in Combination with Paclitaxel for Recurrent or Metastatic HNSCC

ANLAdlai Nortye Ltd.2026-06-26 06:19 EST

Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

ANLAdlai Nortye Ltd.2026-06-26 06:19 EST

Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

ANLAdlai Nortye Ltd.2026-06-26 06:19 EST

Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States